Azilsartan-d5 | CAS#1346599-45-8 | Azilsartan quantification internal standard

MedKoo Cat#: 463969 | Name: Azilsartan-d5

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Azilsartan-d5 is intended for use as an internal standard for the quantification of azilsartan by GC- or LC-MS. Azilsartan is an antagonist of the angiotensin II type 1 receptor and the active metabolite of azilsartan medoxomil. Azilsartan is formed from azilsartan medoxomil by hydrolysis in the gastrointestinal tract and liver. Azilsartan also acts as an inverse agonist, inhibiting angiotensin II-induced accumulation of inositol-1-phosphate in COS-7 cells expressing recombinant human AT1. It reduces the maximal contractile response induced by angiotensin II in isolated rabbit aortic strips. Azilsartan inhibits the angiotensin II-induced pressor response in conscious normotensive rats.

Chemical Structure

Azilsartan-d5

CAS#1346599-45-8 (deuterated forms d5)

Theoretical Analysis

MedKoo Cat#: 463969

Name: Azilsartan-d5

CAS#: 1346599-45-8 (deuterated forms d5)

Chemical Formula: C25H15D5N4O5

Exact Mass: 461.1748

Molecular Weight: 461.49

Elemental Analysis: C, 65.07; H, 5.46; N, 12.14; O, 17.33

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 550.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1824707-75-6 (trimethylethanolamine) 147403-03-0 (free acid) 1346599-45-8 (deuterated forms d5)

Synonym

Azilsartan-d5; Azilsartan d5;

IUPAC/Chemical Name

2-(ethoxy-d5)-1-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylic acid

InChi Key

KGSXMPPBFPAXLY-ZBJDZAJPSA-N

InChi Code

InChI=1S/C25H20N4O5/c1-2-33-24-26-20-9-5-8-19(23(30)31)21(20)29(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-27-25(32)34-28-22/h3-13H,2,14H2,1H3,(H,30,31)(H,27,28,32)/i1D3,2D2

SMILES Code

O=C1NC(C2=C(C3=CC=C(CN4C5=C(C=CC=C5N=C4OC([2H])(C([2H])([2H])[2H])[2H])C(O)=O)C=C3)C=CC=C2)=NO1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 461.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Sinha S, Chary S, Reddy Bandi M, Thakur P, Talluri L, Reddy VK, Agarwal M, Naik K S, Azilsartan Study In Indian Adult Patients Of Essential Hypertension Investigators Azilehi Group. Evaluation of the Efficacy and Safety of Azilsartan in Adult Patients with Essential Hypertension: A Randomized, Phase-III Clinical Study in India. J Assoc Physicians India. 2021 Feb;69(2):35-39. PMID: 33527809. 2: Kumar A, Khrime D. Efficacy and Safety of Azilsartan and Telmisartan in Hypertensive Patients. Saudi J Med Med Sci. 2021 Jan-Apr;9(1):82. doi: 10.4103/sjmms.sjmms_495_20. Epub 2020 Dec 26. PMID: 33519350; PMCID: PMC7839569. 3: Alnajjar R, Mostafa A, Kandeil A, Al-Karmalawy AA. Molecular docking, molecular dynamics, and in vitro studies reveal the potential of angiotensin II receptor blockers to inhibit the COVID-19 main protease. Heliyon. 2020 Dec;6(12):e05641. doi: 10.1016/j.heliyon.2020.e05641. Epub 2020 Dec 3. PMID: 33294721; PMCID: PMC7713577. 4: Kumar A, Loharch S, Kumar S, Ringe RP, Parkesh R. Exploiting cheminformatic and machine learning to navigate the available chemical space of potential small molecule inhibitors of SARS-CoV-2. Comput Struct Biotechnol J. 2021;19:424-438. doi: 10.1016/j.csbj.2020.12.028. Epub 2020 Dec 29. PMID: 33391634; PMCID: PMC7771909. 5: Dong Q, Li Y, Chen J, Wang N. Azilsartan Suppressed LPS-Induced Inflammation in U937 Macrophages through Suppressing Oxidative Stress and Inhibiting the TLR2/MyD88 Signal Pathway. ACS Omega. 2020 Dec 21;6(1):113-118. doi: 10.1021/acsomega.0c03655. PMID: 33458464; PMCID: PMC7807478. 6: Katsi V, Michalakeas C, Soulaidopoulos S, Antonopoulos AS, Vlachopoulos C, Tousoulis D, Tsioufis K. Evaluating the Safety and Tolerability of Azilsartan Medoxomil alone or in combination with Chlorthalidone in the Management of Hypertension: A Systematic Review. Curr Hypertens Rev. 2021 Jan 12. doi: 10.2174/1573402117666210112144505. Epub ahead of print. PMID: 33438552. 7: Meng L, Li Y, Xue C, Ding C, Wang X, Fu R, Li Y, Li X, Dong Z. Compound danshen dripping pills affect the pharmacokinetics of azisartan by regulating the expression of cytochrome P450 2B1, 2C6, and 2C11 in rats. J Pharm Biomed Anal. 2021 Feb 20;195:113887. doi: 10.1016/j.jpba.2020.113887. Epub 2021 Jan 2. PMID: 33418444. 8: Ramírez-Salinas GL, Martínez-Archundia M, Correa-Basurto J, García-Machorro J. Repositioning of Ligands That Target the Spike Glycoprotein as Potential Drugs for SARS-CoV-2 in an In Silico Study. Molecules. 2020 Nov 29;25(23):5615. doi: 10.3390/molecules25235615. PMID: 33260370; PMCID: PMC7731341. 9: Noguchi S, Okochi M, Atsuta H, Kimura R, Fukumoto A, Takahashi K, Nishimura T, Tomi M. Substrate recognition of renally eliminated angiotensin II receptor blockers by organic anion transporter 4. Drug Metab Pharmacokinet. 2021 Feb;36:100363. doi: 10.1016/j.dmpk.2020.10.002. Epub 2020 Oct 24. PMID: 33189558. 10: Maruyama-Fumoto K, McGuire JJ, Fairlie DP, Shinozuka K, Kagota S. Activation of protease-activated receptor 2 is associated with blood pressure regulation and proteinuria reduction in metabolic syndrome. Clin Exp Pharmacol Physiol. 2021 Feb;48(2):211-220. doi: 10.1111/1440-1681.13431. Epub 2020 Nov 21. PMID: 33124085. 11: Chazova IE, Zhernakova YV. An international multicenter observational non- interventional prospective study of the efficacy of azilsartan medoxomil in overweight or obese patients with arterial hypertension (CONSTANT). Curr Med Res Opin. 2020 Dec 7:1-9. doi: 10.1080/03007995.2020.1844647. Epub ahead of print. PMID: 33119420. 12: Abdelaziz MA, Mansour FR, Danielson ND. A gadolinium-based magnetic ionic liquid for dispersive liquid-liquid microextraction. Anal Bioanal Chem. 2021 Jan;413(1):205-214. doi: 10.1007/s00216-020-02992-z. Epub 2020 Oct 23. PMID: 33095289; PMCID: PMC7581952. 13: A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension: Erratum. Medicine (Baltimore). 2020 Sep 4;99(36):e22168. doi: 10.1097/MD.0000000000022168. Erratum for: Medicine (Baltimore). 2020 Aug 7;99(32):e21465. PMID: 32899104; PMCID: PMC7478612. 14: Goldenberg R, Bell A, Cheng W, Fils-Aimé N, Burrows M, Blavignac J, Parron E, Barakat M. Real-world effectiveness of treatments for type 2 diabetes, hypercholesterolemia, and hypertension in Canadian routine care - Results from the CardioVascular and metabolic treatment in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry, 12-months results. Diabetes Res Clin Pract. 2020 Dec;170:108416. doi: 10.1016/j.diabres.2020.108416. Epub 2020 Sep 4. PMID: 32891688. 15: Nagamine T. Lithium Intoxication in the Elderly: A Possible Interaction between Azilsartan, Fluvoxamine, and Lithium. Innov Clin Neurosci. 2020 Apr 1;17(4-6):45-46. PMID: 32802593; PMCID: PMC7413330. 16: Wu J, Du X, Lv Q, Li Z, Zheng Z, Xia Y, Tang C, Yao Z, Zhang J, Long M, Hisada M, Wu J, Zhou W, Ma C. A phase 3 double-blind randomized (CONSORT- compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension. Medicine (Baltimore). 2020 Aug 7;99(32):e21465. doi: 10.1097/MD.0000000000021465. Erratum in: Medicine (Baltimore). 2020 Sep 4;99(36):e22168. PMID: 32769878; PMCID: PMC7505320. 17: Kwon A, Kim GH. Single-pill Combination Therapy of Azilsartan Medoxomil/Chlorthalidone for Treatment of Hypertension: A Systematic Review. Clin Ther. 2020 Jul;42(7):1390-1403. doi: 10.1016/j.clinthera.2020.05.015. Epub 2020 Jun 25. PMID: 32595000. 18: Garg M, Manik G, Singhal A, Singh VK, Varshney RK, Sethi A. Efficacy and Safety of Azilsartan Medoxomil and Telmisartan in Hypertensive Patients: A Randomized, Assessor-Blinded Study. Saudi J Med Med Sci. 2020 May- Aug;8(2):87-94. doi: 10.4103/sjmms.sjmms_19_19. Epub 2020 Apr 17. PMID: 32587489; PMCID: PMC7305670. 19: Drugs for hypertension. Med Lett Drugs Ther. 2020 May 18;62(1598):73-80. PMID: 32555118. 20: Goldenberg R, Bell A, Cheng W, Paron E, Fils-Aimé N, Burrows M, Blavignac J, Barakat M. Regional variability in Canadian routine care of type 2 diabetes, hypercholesterolemia, and hypertension: Results from the The Cardio-Vascular and metabolic treatments in Canada: Assessment of REal-life therapeutic value (CV- CARE) registry. J Cardiol. 2020 Oct;76(4):385-394. doi: 10.1016/j.jjcc.2020.04.008. Epub 2020 May 27. PMID: 32473770.